secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K/A
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-257298
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences reports positive WVE-007 target engagement: up to 85% Activin E reduction; WVE-008 candidate selected
--------------------------------------------------------------------------------

- WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.
- WVE-007 safe/well-tolerated; DMC cleared dose expansion to 600mg and beyond. Body composition/weight data updates expected starting 4Q2025.
- WVE-008 selected as PNPLA3-I148M RNA editing candidate for liver disease; CTA filing expected in 2026. Estimated 9M homozygous patients in US/EU.
- WVE-006 AATD cohort 3 (600mg) now underway; previously restored 13 µM total AAT with 64% M-AAT. Multidose data expected 1Q2026.
- Platform data: single oligonucleotide can simultaneously edit and silence two targets (LDLR up, PCSK9 down) in preclinical models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525257298/0001193125-25-257298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525257298/d59691d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-257298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer